SCHEMBL1745191

SCHEMBL1745191

COC(=O)CCc1ccc(OCc2cc3ccccc3[nH]2)cc1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.48
PDGFRA P16234 2/20 0.48
FFAR1 O14842 9/20 0.47
FFAR4 Q5NUL3 3/20 0.47
VDR P11473 2/20 0.47
PPARD Q03181 1/20 0.46
MTNR1A P48039 1/20 0.46
MTNR1B P49286 1/20 0.46
AKR1B1 P15121 2/20 0.46
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ADRB2 P07550 1/20 0.44
ADRB1 P08588 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6516292 0.90 FFAR1 (0.49) PDGFRBPDGFRAFFAR1PPARDMTNR1A
SCHEMBL1744999 0.88 FFAR1 (0.62) FFAR1FFAR4AKR1B1
SCHEMBL9108723 0.82 MTNR1A (0.61) MTNR1AMTNR1BKDM4EALDH1A1SMN1; SMN2
SCHEMBL1746499 0.80 RAB9A (0.55) FFAR1FFAR4VDRAKR1B1
SCHEMBL6516755 0.79 ALDH1A1 (0.50) PDGFRBPDGFRAFFAR1PPARDMTNR1A
SCHEMBL853651 0.78 KDM4E (0.60) PDGFRBPDGFRAFFAR1MTNR1AMTNR1B
SCHEMBL27839236 0.77 MTNR1A (0.58) MTNR1AMTNR1BKDM4EALDH1A1SMN1; SMN2
SCHEMBL1745247 0.77 FFAR1 (0.72) FFAR1FFAR4AKR1B1SMN1; SMN2
SCHEMBL1747136 0.77 FFAR1 (0.72) FFAR1FFAR4AKR1B1SMN1; SMN2
SCHEMBL27622018 0.77 TAS1R3 (0.45) PDGFRBPDGFRAPPARDMTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR PDGFRB 748/4885PDGFRA 679/4885FFAR1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.